COVID VLP

SARS-CoV-2 virus-like particles (VLPs) are non-infectious nanoparticles designed to mimic the structure and antigenicity of the SARS-CoV-2 virus, the causative agent of COVID-19. These VLPs lack viral RNA, making them a safe and effective tool for vaccine development, diagnostics, and immunological research. 

Structure of SARS-CoV-2 VLPs

SARS-CoV-2 VLPs are composed of structural proteins that assemble into particles resembling the native virus:

  • Spike Protein (S): Responsible for binding to the host receptor ACE2; the primary target for neutralizing antibodies.
  • Envelope Protein (E): Involved in particle assembly and release.
  • Membrane Protein (M): Provides structural integrity to the VLP.
  • Nucleocapsid Protein (N): Enhances VLP immunogenicity by mimicking the virus's nucleocapsid.
Production Systems

SARS-CoV-2 VLPs are produced in a variety of expression systems:

  • Mammalian Cells: Preferred for their ability to generate glycosylation and post-translational modifications similar to native SARS-CoV-2.
  • Insect Cells: Used for high-yield production with proper folding and functionality of spike proteins.
  • Plant-Based Systems: Emerging as scalable and cost-effective platforms for producing VLPs.
  • Yeast Systems: Offer high production efficiency but may require optimization for glycosylation patterns.
Applications
  • Vaccines
    • Prophylactic Vaccines: SARS-CoV-2 VLP-based vaccines aim to induce robust immune responses, including neutralizing antibodies against the spike protein and T-cell responses.
    • Multivalent Vaccines: Designed to incorporate antigens from multiple SARS-CoV-2 variants to enhance cross-protection.
  • Diagnostics
    • VLPs serve as antigens in serological assays to detect SARS-CoV-2-specific antibodies, aiding in diagnosis and monitoring immune responses.
  • Immunological Research
    • Used to study immune responses to SARS-CoV-2 infection, including mechanisms of neutralization and memory B-cell activation.

SARS-CoV-2 virus-like particles represent a cutting-edge platform in the fight against COVID-19, offering safety, strong immunogenicity, and adaptability. Ongoing advancements in VLP technology aim to improve vaccine accessibility, efficacy, and long-term protection, solidifying their role in combating the current pandemic and preparing for future outbreaks.

AffiVLP® COVID-19 VLP (S; Null Protein)
CAT# AFG-VLP-151
Size: 100 µg
For Price Contact info@affigen.com 0.0 USD
AffiVLP® COVID-19 VLP (S; Luciferase)
CAT# AFG-VLP-150
Size: 100 µg
For Price Contact info@affigen.com 0.0 USD